151 related articles for article (PubMed ID: 37993584)
1. NPLOC4 is a potential target and a poor prognostic signature in lung squamous cell carcinoma.
Wang N; Zhu D; Liu Y; Wu J; Wang M; Jin S; Fu F; Li B; Ji H; Du C; Zheng Z
Sci Rep; 2023 Nov; 13(1):20430. PubMed ID: 37993584
[TBL] [Abstract][Full Text] [Related]
2. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
[TBL] [Abstract][Full Text] [Related]
3. The necroptosis signature and molecular mechanism of lung squamous cell carcinoma.
Song GQ; Wu HM; Ji KJ; He TL; Duan YM; Zhang JW; Hu GQ
Aging (Albany NY); 2023 Nov; 15(22):12907-12926. PubMed ID: 37976123
[TBL] [Abstract][Full Text] [Related]
4. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
5. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
[TBL] [Abstract][Full Text] [Related]
6. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
[TBL] [Abstract][Full Text] [Related]
7. Integrative Analysis of Pyroptosis-Related Prognostic Signature and Immunological Infiltration in Lung Squamous Cell Carcinoma.
Luo P; Jiang Y; Ding S; Jiang S; Tang R; Tang Z
Biomed Res Int; 2022; 2022():4944758. PubMed ID: 35692583
[TBL] [Abstract][Full Text] [Related]
8. Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer.
Wu X; Xue X; Wang L; Wang W; Han J; Sun X; Zhang H; Liu Y; Che X; Yang J; Wu C
Eur J Pharmacol; 2018 May; 827():1-12. PubMed ID: 29547841
[TBL] [Abstract][Full Text] [Related]
9. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
Xu F; Zhang H; Chen J; Lin L; Chen Y
Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a prognostic model toward lung squamous cell carcinoma based on m
Wang Y; Liu Y; Wang R; Cao F; Guan Y; Chen Y; An B; Qin S; Yao S
Physiol Genomics; 2023 Oct; 55(10):427-439. PubMed ID: 37575065
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients.
Liu X; Zhao D; Shan Y; Cui W; Xie Q; Jiang J; Peng W; Zhang C; Duan C
Sci Rep; 2022 Dec; 12(1):20737. PubMed ID: 36456645
[TBL] [Abstract][Full Text] [Related]
12. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
[TBL] [Abstract][Full Text] [Related]
13. Identification of tumour-infiltrating myeloid subsets associated with overall survival in lung squamous cell carcinoma.
Lu J; Duan Y; Liu P; He X; Yang Y; Zhang R; Weng L
J Pathol; 2023 Jan; 259(1):21-34. PubMed ID: 36178315
[TBL] [Abstract][Full Text] [Related]
14. A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
Huang G; Zhang J; Gong L; Huang Y; Liu D
BMC Cancer; 2021 May; 21(1):626. PubMed ID: 34044809
[TBL] [Abstract][Full Text] [Related]
15. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
Zhang Y; Zhou J; Li H; Liu Y; Li J
BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
[TBL] [Abstract][Full Text] [Related]
16. Role of downregulated ADARB1 in lung squamous cell carcinoma.
Wang X; Ren X; Liu W; Chen X; Wei J; Gong Z; Yan Y; Xu Z
Mol Med Rep; 2020 Mar; 21(3):1517-1526. PubMed ID: 32016472
[TBL] [Abstract][Full Text] [Related]
17. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
Yan D; Chen Y
Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis-related genes.
Diao X; Guo C; Liu L; Wang G; Li S
Thorac Cancer; 2021 Dec; 12(23):3236-3247. PubMed ID: 34672420
[TBL] [Abstract][Full Text] [Related]
19. A nine-long non-coding RNA signature for prognosis prediction of patients with lung squamous cell carcinoma.
Huang G; Huang Q; Xie Z; Zhou H; Cao J; Shi L; Yang M
Cancer Biomark; 2019; 26(3):239-247. PubMed ID: 31524143
[TBL] [Abstract][Full Text] [Related]
20. CISD2 promotes lung squamous carcinoma cell migration and invasion via the TGF-β1-induced Smad2/3 signaling pathway.
Zhang J; Pan L; Zhang S; Yang Y; Liang J; Ma S; Wu Q
Clin Transl Oncol; 2023 Dec; 25(12):3527-3540. PubMed ID: 37249759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
